Tumor Biology

, Volume 37, Issue 7, pp 8979–8983 | Cite as

Circulating serum levels of angiopoietin-1 and angiopoietin-2 in nasopharynx and larynx carcinoma patients

  • Murat Emin Güveli
  • Derya Duranyildiz
  • Ahmet Karadeniz
  • Elif Bilgin
  • Murat Serilmez
  • Hilal Oguz Soydinc
  • Vildan Yasasever
Original Article


We aimed to determine the serum levels of angiogenic factors, namely angiopoietins, in nasopharyngeal and laryngeal carcinoma patients. We also aimed to seek the relation of these molecules with tumor grade and their utility as diagnostic biomarkers. We evaluated angiopoietin 1 and 2 levels innasopharynx and larynx cancer patients before treatment. Angiopoietin 2 levels were significantly elevated in larynx carcinoma patients and tended to be elevated in nasopharynx cancer patients compared with healthy controls. However, angiopoietin 1 levels were similar in cancer patients and controls. Angiopoietin 1 levels were significantly higher in nasopharyngeal cancer patients with advanced stages compared to earlier stages. On the other hand, angiopoietin 2 levels were similar in advanced and earlier stage cancer patients.


Angiopoietins Nasopharynx cancer Larynx cancer 


Compliance with ethical standards

Conflicts of interest



  1. 1.
    Carla C, Daris F, Cecilia B, Francesca B, Francesca C, Paolo F. Angiogenesis in head and neck cancer: a review of the literature. J Oncol. 2012;2012:358472.CrossRefPubMedGoogle Scholar
  2. 2.
    Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Med Oncol. 2008;25:431–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Demasi AP, Silva CA, Silva AD, Furuse C, Soares AB, Altemani A, et al. Expression of the vascular endothelial growth factor and angiopoietins in mucoepidermoid carcinoma of salivary gland. Head Neck Pathol. 2012;6:10–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Melen-Mucha G, Niedziela A, Mucha S, Motylewska E, Lawnicka H, Komorowski J, et al. Elevated peripheral blood plasma concentrations of tie-2 and angiopoietin 2 in patients with neuroendocrine tumors. Int J Mol Sci. 2012;13:1444–60.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer. 2010;10:575–85.CrossRefPubMedGoogle Scholar
  6. 6.
    Bessa V, Loukides S, Hillas G, Delimpoura V, Simoes D, Kontogianni K, et al. Levels of angiopoietins 1 and 2 in induced sputum supernatant in patients with COPD. Cytokine. 2012;58:455–60.CrossRefPubMedGoogle Scholar
  7. 7.
    Gardizi M, Kurschat C, Riese A, Hahn M, Krieg T, Mauch C, et al. A decreased ratio between serum levels of the antagonistic angiopoietins 1 and 2 indicates tumour progression of malignant melanoma. Arch Dermatol Res. 2012;304:397–400.CrossRefPubMedGoogle Scholar
  8. 8.
    Karatzanis AD, Koudounarakis E, Papadakis I, Velegrakis G. Molecular pathways of lymphangiogenesis and lymph node metastasis in head and neck cancer. Eur Arch Otorhinolaryngol. 2012;269:731–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Volkova E, Willis JA, Wells JE, Robinson BA, Dachs GU, Currie MJ. Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br J Cancer. 2011;104:51–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Wieloch M, Swiatkowska M, Libiszewski M, Hedayati M, Drozda R, Kolomecki K. Assessment of the selected, late phase of angiogenesis factors’ concentration in colorectal cancer patients. Pol Merkur Lekarski. 2009;27:466–9.PubMedGoogle Scholar
  11. 11.
    Sallinen H, Heikura T, Laidinen S, Kosma VM, Heinonen S, Yla-Herttuala S, et al. Preoperative angiopoietin-2 serum levels: a marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20:1498–505.PubMedGoogle Scholar
  12. 12.
    Yuan HT, Khankin EV, Karumanchi SA, Parikh SM. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol. 2009;29:2011–22.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hu B, Cheng SY. Angiopoietin-2: development of inhibitors for cancer therapy. Curr Oncol Rep. 2009;11:111–6.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ribatti D, Vacca A, Presta M. The discovery of angiogenic factors: a historical review. Gen Pharmacol. 2000;35:227–31.CrossRefPubMedGoogle Scholar
  15. 15.
    Chien CY, Su CY, Chuang HC, Fang FM, Huang HY, Chen CM, et al. Angiopoietin-1 and -2 expression in recurrent squamous cell carcinoma of the oral cavity. J Surg Oncol. 2008;97:273–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Mitsutake N, Namba H, Takahara K, Ishigaki K, Ishigaki J, Ayabe H, et al. Tie-2 and angiopoietin-1 expression in human thyroid tumors. Thyroid. 2002;12:95–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Nagata J, Kijima H, Hatanaka H, Tokunaga T, Kamochi J, Abe Y, et al. Angiopoietin-1 and vascular endothelial growth factor expression in human esophageal cancer. Int J Mol Med. 2002;10:423–6.PubMedGoogle Scholar
  18. 18.
    Xu G, Lou W, Sun Z, Zhang P. Expression of angiopoietin-1, 2 and its relationship with angiogenesis in laryngeal squamous cell carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2008;22:772–6.PubMedGoogle Scholar
  19. 19.
    Li C, Feng HC, Chen JC, Song YF. Expression and significance of angiopoietin-1 and angiopoietin-2 in oral squamous cell carcinoma. Ai Zheng. 2005;24:1388–93.PubMedGoogle Scholar
  20. 20.
    Li C, Zhang B, Wang ZH, Chen JC, Li B, Wang SX, et al. Significance of a reversal expression of the angiopoietin-1 and 2 in oral squamous cell carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009;44:412–8.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Murat Emin Güveli
    • 1
  • Derya Duranyildiz
    • 1
  • Ahmet Karadeniz
    • 1
  • Elif Bilgin
    • 1
  • Murat Serilmez
    • 1
  • Hilal Oguz Soydinc
    • 1
  • Vildan Yasasever
    • 1
  1. 1.Istanbul University Oncology InstituteIstanbulTurkey

Personalised recommendations